Who is sponsoring NCT04782193?

NCT04782193 is sponsored by Chongqing Precision Biotech Co., Ltd.

What drugs are being tested in NCT04782193?

Interventions in NCT04782193: CD19 and CD22 targeted prime CAR- T cells.

What condition does NCT04782193 study?

NCT04782193 studies B Cell Lymphoma.

Is NCT04782193 still recruiting?

NCT04782193 is currently status unknown. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT04782193

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Status unknown Phase 1, PHASE2 Last updated 18 April 2023

What this trial tests

Phase 1, PHASE2 trial testing CD19 and CD22 targeted prime CAR- T cells in B Cell Lymphoma in 40 participants. Status unknown.

Timeline

23 May 2021

Primary endpoint
31 December 2023

1 July 2024

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	23 May 2021
Primary completion	31 December 2023
Estimated completion	1 July 2024
Sites	1 location across China

Drugs / interventions tested

CD19 and CD22 targeted prime CAR- T cells — full drug profile →

Conditions studied

B Cell Lymphoma — all drugs for B Cell Lymphoma →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

Adults 2 to 75, any sex, with B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M, Nowak E, Twardowska J, Lejman M, et al · · 2023 · cited 5× · PMID 38003910 · DOI 10.3390/jpm13111595

Verify or expand the search:

Other recruiting trials for B Cell Lymphoma

Currently open trials in the same condition.

NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT06976437 — A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors · EARLY_PHASE1 · recruiting
NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
NCT06742996 — A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Phase 3 · recruiting

Other Chongqing Precision Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04782193 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04782193.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing